Oncol Reports 2008, 19:843–846. 35. Goumenou AG, Arvanitis DA, Matalliotakis IM, Koumantakis EE, Spandidos DA: Microsatellite DNA assays reveal an allelic imbalance in p16(Ink4), GALT, p53, and APOA2 loci in patients with endometriosis. Fertil Steril 2001, 75:160–165.PubMedCrossRef 36. Mammas IN, Zafiropoulos A, Spandidos DA: Involvement of the ras genes

in female genital tract cancer. Int J Oncol 2005, 26:1241–1255.PubMed 37. Chung HW, Wen Y, Chun SH, Nezhat C, Woo BH, Lake PM: Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis: a rationale for endometriotic invasiveness. TGF-beta inhibitor Fertil Steril 2001,75(1):152–159.PubMedCrossRef 38. Chen QH, Zhou WD, Pu DM, Huang QS, Li T, Chen QX: 15-Epi-lipoxin A(4) inhibits the progression of endometriosis in a murine model. Fertil Steril 2009, in press. 39. Kirn-Safran CB, D’Souza SS, Carson DD: Heparan sulfate proteoglycans

and their binding proteins in embryo implantation Captisol clinical trial and placentation. Semin Cell Dev Biol 2008, 19:187–193.PubMedCrossRef 40. Berardo PT, Abrão MS, Souza ML, Machado DE, Silva LC, Nasciutti LE: Composition of sulfated glycosaminoglycans and immunodistribution of chondroitin sulfate in deeply infiltrating endometriosis affecting the rectosigmoid. Micron 2009, 40:639–45.PubMedCrossRef 41. Nasciutti LE, Ferrari R, Berardo PT, Souza MLS, Takiya CM, Borojevic R, Abrao MS, Silva LCF: Distribution of chondroitin sulfate in human endometrium.

Micron 2006, 37:544–550.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions DEM participated in the design, data acquisition, manuscript writing, carried out statistical analyses and have given final approval of the version to be published. PTB participated in study design and revised manuscript. CYP performed data analysis and helped to draft the manuscript. LEN check details supervised the design of the experiments and analyzed and interpreted of data. All authors approved the final manuscript.”
“Background Basic fibroblast growth DNA ligase factor (bFGF) is a heparin-binding growth factor that is secreted as a pleiotropic protein and can act on various cell types, including tumor cells. bFGF is hypothesized to have a critical role in the development of the nervous system [1], and for gliomas, the level of bFGF present has been shown to correlate with tumor grade and clinical outcome [2], bFGF has also been shown to be up-regulated in transformed glial cells and to be overexpressed in malignant gliomas [3]. bFGF exerts its cellular functions through the binding of four FGF receptors (FGFRs), all of which are receptor tyrosine kinases (RTKs). The binding of bFGF by FGFRs recruits and activates several signaling pathways [4]. Accordingly, down-regulation of bFGF using antibodies or antisense sequences has been shown to inhibit tumor cell tumorigenicity and metastasis [3, 5, 6].